News & Updates

Tumour burden, as assessed by imaging techniques, appears to substantially influence outcomes in patients with recurrent or metastatic head and neck cancer (RM-HNC) treated with immune checkpoint inhibitors (ICI), a recent study has found.

Salivary levels of miRNA-21 and miRNA-31 appear to correlate with the onset and progression of oral potentially malignant disorders (OPMD) and could be used as noninvasive biomarkers for screening, a recent study has found.

The combination of nivolumab 1 mg/kg (NIVO1) and ipilimumab 3 mg/kg (IPI3) every 3 weeks followed by NIVO 240 mg every 2 weeks in the second-line setting continues to confer durable response and overall survival (OS) benefit in patients with advanced hepatocellular carcinoma (aHCC), according to 5-year data from the CheckMate 040* trial presented at ESMO GI 2022.

The benefit of adding durvalumab to gemcitabine plus cisplatin chemotherapy in patients with advanced biliary tract cancer (BTC) was consistent regardless of primary tumour location, according to a subgroup analysis of the phase III TOPAZ-1 study presented at ESMO GI 2022.